These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31845320)

  • 1. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
    Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
    Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
    Benbrook DM; Nammalwar B; Long A; Matsumoto H; Singh A; Bunce RA; Berlin KD
    Invest New Drugs; 2014 Jun; 32(3):412-23. PubMed ID: 24254390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
    Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
    Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
    Watts FM; Pouland T; Bunce RA; Berlin KD; Benbrook DM; Mashayekhi M; Bhandari D; Zhou D
    Eur J Med Chem; 2018 Oct; 158():720-732. PubMed ID: 30245396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
    Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
    Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Elayapillai S; Ramraj S; Benbrook DM; Bieniasz M; Wang L; Pathuri G; Isingizwe ZR; Kennedy AL; Zhao YD; Lightfoot S; Hunsucker LA; Gunderson CC
    Gynecol Oncol; 2021 Jan; 160(1):302-311. PubMed ID: 33131904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Effects of PRIMA-1 and PRIMA-1
    Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
    Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
    Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
    Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
    Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
    Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
    Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
    J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.